Yoga for quitting tobacco addictio

Phase 2

• Conditions: Health Condition 1: F172- Nicotine dependence

• Registration Number: CTRI/2021/12/038745
• Lead Sponsor: Centre for Integrative Medicine and Research CIMR

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 February 2022

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

a) Smoking rate of at least 5 cigarettes/bidi per day

or at least 5 times a day use of smokeless

tobacco such as zarda (khani), gutka

b) Adults between the age range of 18-65 years

c) Willing and able to participate in 45 min of

moderately intense exercise or yoga,

d) No contraindications for moderate-intensity

exercise based on the Physical Activity

Readiness Questionnaire (Thomas, Reading, &

Shephard, 1992)

Exclusion Criteria

a) Currently practicing regular exercise and yoga for

more than 3 times per week.

b) Currently enrolled in a quit-smoking program,

c) Had a medical condition that might make

participation in yoga difficult or potentially

hazardous (e.g., heart failure NYHA Class III and

Class IV, ischemia Class II, uncontrolled

hypertension; COPD grade 3 and 4)

d) Other substance abuse such as alcohol (more

than 4 drinks on any day for men or more than 3

drinks for women; NIAAA, 2021)or opioid

dependency

e) Taking benzodiazepines, antidepressants,

neuroleptics, anticonvulsants, or major

tranquilizers.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Salivary cotinineTimepoint: baseline and 6 months

Secondary Outcome Measures

Name	Time	Method
Brief WISDM (-Wisconsin inventory of smoking dependence motives)Timepoint: baseline, 2 (end of treatment), 3 and 6 months;Depression Anxiety Stress Scale (DASS)Timepoint: baseline, 2 (end of treatment), 3 and 6 months;Fagerstrom Nicotine Dependence (FTND)Timepoint: Baseline, 2 (end of treatment), 3 and 6 months;self reported 30 days point prevalence abstinenceTimepoint: 2 (end of treatment), 3 and 6 months;self reported 7 days point prevalence abstinenceTimepoint: 2 (end of treatment), 3 and 6 months;Severson Smokeless Tobacco Dependence ScaleTimepoint: Baseline, 2 (end of treatment), 3 and 6 months;smoke/smokeless percentage reductionTimepoint: baseline, 2 (end of treatment), 3 and 6 months;Smoking self-efficacy scaleTimepoint: baseline, 2 (end of treatment), 3 and 6 months;Smoking Situation Temptation ScaleTimepoint: baseline, 2 (end of treatment), 3 and 6 months;WHOQOL (BREF)Timepoint: baseline, 2 (end of treatment), 3 and 6 months;Withdrawal ScaleTimepoint: baseline, 2 (end of treatment), 3 and 6 months